Agile's Twirla Suffers Scathing Critique By US FDA Ahead Of Advisory Cmte.

Agile's transdermal contraceptive will go before the Bone, Reproductive and Urologic Drugs Advisory Committee as it nears the end of its third review cycle, although the agency appears ready to issue another complete response letter before it even hears from the panel.